Factor V Arg506Gln mutation is not associated with cardiovascular mortality in older women

American Journal of Epidemiology

Volumn 149, Issue 7, 1999, Pages 665-670

  Roest, Mark ^a   Banga, Jan Dirk ^a   Tempelman, Mariëlle J ^a   De Groot, Philip G ^a   Grobbee, Diederick E ^a   Sixma, Jan J ^a   Van Der Schouw, Yvonne T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular diseases; Cerebrovascular disorders; Cohort studies; Factor V; Mortality; Myocardial infarction; Postmenopause; Women

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 5A; GLUTAMINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; HETEROZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; MUTANT; RISK FACTOR; SMOKING; VEIN THROMBOSIS;

EID: 0033119947     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009867     Document Type: Article

References (25)

1. Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995;270:27852-8.
2. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein. J Biol Chem 1995;270:21158-66.
3. Aparicio C, Dahlback B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J 1996;313:467-72.
4. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C (see comments). Nature 1994;369:64-7.
5. Zoller B, Svensson PJ, He X, et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1996;94:2521-4.
6. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-17.
7. Majerus PW. Human genetics. Bad blood by mutation (news; comment). Nature 1994;369:14-15.
8. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
9. Marz W, Seydewitz H, Winkelmann B, et al. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. (Letter). Lancet 1995;345:526.
10. Holm J, Zoller B, Berntorp E, et al. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996;239:221-6.
11. Kontula K, Ylikorkala A, Miettinen H, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995;73:558-60.
12. Ardissino D, Peyvandi F, Merlini PA, et al. Factor V (Arg 506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996;75:701-2.
13. van der Bom JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265-9.
14. Hille ET, Westendorp RG, Vandenbroucke JP, et al. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997;89:1963-7.
15. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-21.
16. Doggen CJ, Cats VM, Bertina RM, et al. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:1037-41.
17. deWaard F, Collette HJA, Rombach JJ, et al. The DOM-project for early diagnosis of breast cancer. J Chronic Dis 1984;47:41-4.
18. Miettinen OS. Estimability and estimation in case-referent studies. Am J Epidemiol 1976;103:226-35.
19. Verduyn W, Doxiadis II, Anholts J, et al. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol 1993;37:59-67.
20. Hardy GH. Mendelian proportions in mixed population. Science 1908;28:41-50.
21. Weinberg W. On demonstration of heredity in man. Papers of human genetics. Englewood Cliffs, NJ: Prentice-Hall, 1963.
22. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. Proc Fifth Berkeley Symp Math Stat Prob 1967;1:221-33.
23. Zimmerman FH, Cameron A, Fisher LD. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995;26:654-61.
24. Marenberg ME, Risch N, Berkman LF, et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041-6.
25. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation (see comments). Lancet 1994;344:1453-7.